• Total revenue A$10,867m, up 13% year-on-year
• Strong organic revenue growth 5%
• Completed major German acquisition - LADR
• US operating review ongoing to improve profitability and ROIC
• Strong growth in advanced diagnostics and direct-to-consumer testing

Sonic Healthcare Ltd reported a 13% year-on-year increase in total revenue to A$10.87 billion for the year ended 30 June 2026. The company achieved its EBITDA guidance of A$1.93 billion, with underlying EBITDA at A$1.916 billion. Net profit rose 17% to A$621 million, and earnings per share increased 14% to 125.6 cents. The company completed the acquisition of LADR in Germany, with over 40% of expected synergies already realized. The US operating review is ongoing, with initiatives expected to add A$25-30 million to FY2027 earnings. Advanced diagnostics and direct-to-consumer testing saw strong growth. The company also completed the sale and leaseback of its Brisbane hub laboratory.

FY2027: Revenue growth of 13%, EBITDA growth of 11%, and net profit growth of 17%

Sonic Healthcare is focused on growing earnings per share and improving return on invested capital to drive long-term value creation. The company is also pursuing growth opportunities in advanced diagnostics and direct-to-consumer testing.